NASDAQ OMX

Bermuda's global business sector showcased in London

Dela

HAMILTON, Bermuda, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Leaders of Bermuda's global business sector highlighted the breadth, advantages and significant economic impact of the island's financial market during an awareness-raising cross-industry forum held in London today by the Bermuda Business Development Agency (BDA).

Photos accompanying this announcement are available at:
http://www.globenewswire.com/NewsRoom/AttachmentNg/2bcaa95b-e3ca-44c9-899a-cb70eeb4cf10 
http://www.globenewswire.com/NewsRoom/AttachmentNg/7bdeef31-44cc-4e6d-9984-f08a6cd6bfe7 
http://www.globenewswire.com/NewsRoom/AttachmentNg/edb31e57-95aa-4327-8abb-47277d9619a2

Premier the Hon David Burt officially opened the day-long forum after meeting with Britain's Prime Minister Theresa May. The Premier is in the city for the BDA event as well as annual Joint Ministerial Council (JMC) meetings and various Parliamentary events, followed by planned visits to Paris and Berlin later in the week.

"Our government supports events like this BDA forum, because it's important to engage people from around the world to help accomplish our goals growing Bermuda's economy," said the Premier. "Bermuda has a very powerful story to tell as a well-regarded international financial centre known for robust regulation and leadership on transparency and compliance. We believe this is an excellent platform to talk about Bermuda's role in supporting global economies. It's important, because we trade on that reputation."

The forum attracted close to 250 delegates, encompassing a wide range of industries, to ME London Hotel in the city's West End. Featuring top regulatory and industry representatives in discussion panels, the agenda covered hot-button topics such as Brexit and the recent theft of "Paradise Papers" law-firm data, while emphasising the many elements that differentiate Bermuda-from the island's world-respected regulator and access to capital to its deep pool of valuable industry expertise. Speakers also examined the varied sectors that make Bermuda a centre of excellence, including re/insurance, captive insurance and insurance-linked securities, to asset management, family offices, and trust and private-client business.

"The forum has provided us with an opportunity to tell the Bermuda story at a critical juncture when the European spotlight is on international financial centres," said BDA CEO Ross Webber. "Our jurisdiction has a compelling message, and people are beginning to understand that Bermuda really is different."

Forum panels in the morning covered risk-industry topics-from insurance trends and the outlook for 2018 to why Bermuda remains "the World's Risk Capital." Afternoon sessions focused on the rapidly-growing convergence of re/insurance and asset management, then moved to examine high-net-worth services, family governance and charitable trust structuring.

The day's line-up featured 25 Bermuda executives, including Bermuda Monetary Authority CEO Jeremy Cox; Bermuda Stock Exchange CEO Greg Wojciechowski; Association of Bermuda Insurers & Reinsurers President Brad Kading; Grainne Richmond, President of the Bermuda Insurance Management Association (BIMA); and Keith Robinson, Chairman of the Society of Trust & Estate Practitioners (STEP) Bermuda.

Keynote speaker, Deputy Chair of Lloyd's and Hiscox Chair Robert Childs, described Bermuda's speed to market and detailed the many advantages Bermuda had lent to Hiscox.

"The forum gathered government, industry and regulatory experience to give attendees an opportunity to be exposed to the Bermuda market," said BMA CEO Jeremy Cox. "That kind of collaboration is part of what has made Bermuda successful. Certainly, given the times we're in, that's important-because there's been a lot of misinformation in the media about our jurisdiction. This has given us an opportunity to set the record straight."

Other Bermuda-based executive participants included Mark Allitt of KPMG Bermuda; Sarah Demerling of Estera; BDA former chair and Hiscox Director Caroline Foulger; David Gibbons of PwC Bermuda; Ed Granski for Meritus Trust; Randall Krebs of Harbour International Trust Company; BDA Board member Jessel Mendes, of EY Bermuda; Michael Neff of Butterfield Bank; Michael Parrish of Marsh Bermuda; Peter Pearman of Conyers Dill & Pearman; Brian Quinn of Granite Management; Fozeia Rana-Fahy of MJM; Aon CEO Joe Rego; Andrew Smith of Qatar Re; Ariane West of Taylors in association with Walkers; Arthur Wightman of PwC Bermuda; Kim Willey of ASW Law; and Akilah Wilson of the BMA.

"We were very impressed by the support not just from Bermuda industry but from friends of Bermuda here in the UK," Webber added. "We had over 20 different companies represented at our forum; that's a marvellous endorsement of the work of the BDA, and a great reflection of the collaboration of the Bermuda market. It's very rewarding to see Bermuda so well represented and supported."

Overseas presenters included Richard Hay of Stikeman Elliott, London; Siân Hill of KPMG UK; and Samantha Morgan of RMW Law.

"It's about working relationships with the right people - we're not just marketing the jurisdiction," said Jessel Mendes, a BDA Board member and Partner at EY Bermuda. "We're really selling, and I think that's critical. It's about working the relationships with the right people to bring business back to Bermuda. Today, the focus is on the relationship, on business development, and on sales. That's a new mindshift and I believe credit for it goes to the BDA."

Tomorrow, a second industry event-"Beyond Convergence"-will also take place at the hotel, focusing solely on insurance-linked securities. Organised by ILS Bermuda to dovetail with today's forum, it will provide a more detailed look at Bermuda's success in attracting capital, expertise and clients to the sphere of alternative reinsurance. Featured speakers will include some of the same industry executives, including the BSX's Wojciechowski, the BMA's Cox, ABIR's Kading, and BDA's Webber.

MEDIA CONTACT:
Rosemary Jones
Head of Communications & Marketing
rosemary@bda.bm 441 278-6558
441 337-4696

CONNECTING BUSINESS

The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bermuda Business Development Agency (BDA) via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Hoylu AB: HOYLU HIRES NEW CTO, SATOSHI NAKAJIMA AND ANNOUNCES EXPANSION INTO JAPAN14.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 14, 2018 - Hoylu, a leading enterprise collaboration company, announced today Satoshi Nakajima will join Hoylu in the newly created position, as Chief Technology Officer and President of Hoylu Japan. Nakajima will guide the strategic technology direction and innovation of Hoylu while also leading the new Hoylu office in Tokyo, Japan. "Satoshi is a visionary and world-class technologist who has substantial experience in delivering world class innovations. He is joining the Company as we are extending our reach and expanding into Japan," said Stein Revelsby, CEO. "Satoshi's extensive experience in strategy and delivering technology that support a great user experience will make an immediate impact on the company." Nakajima will serve as President of Hoylu Japan and will report to Stein Revelsby. His leadership will strengthen customer relations and help develop new business among emerging and established Japanese companies while strengthening the global position

Hoylu AB: HOYLU ANSTÄLLER SATOSHI NAKAJIMA SOM NY CTO OCH EXPANDERAR TILL JAPAN14.9.2018 08:30Pressmeddelande

Malmö, Sverige, 14 september 2018 - Hoylu, ett ledande företag inom samarbetsmjukvara för företagsmarknaden annonserar idag att Satoshi Nakajima tar anställning som CTO (Chief Technology Officer) och President för Hoylu Japan. Nakajima kommer styra den strategiska inriktningen för företagets produkter och leda innovationsarbetet. Han kommer också leda Hoylus nyöppnade kontor i Tokyo, Japan. Satoshi är en visionär teknologiexpert som har stor erfarenhet av att skapa innovativa lösningar. Han kommer till Hoylu samtidigt som vi utökar marknaden till att även täcka in Japan säger Stein Revelsby, VD. "Satoshis långa och gedigna erfarenhet i strategiska frågor och tekniska lösningar med fokus på användarupplevelse kommer få stor betydelse för oss." Nakajima kommer även att bli President för Hoylu Japan och kommer rapportera till Stein Revelsby. Hans ledarskap kommer stärka existerande kundrelationer och utveckla nya affärer på den japanska marknaden och samtidigt bidra till att flytta fram p

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum